Targeting the mevalonate pathway to overcome acquired anti-HER2 treatment resistance in breast cancer

Despite effective strategies, resistance (R) in HER2+ breast cancer (BC) remains a challenge. While the Mevalonate pathway (MVA) is suggested to promote cell growth and survival, including in HER2+ models, its potential role in resistance to HER2-targeted therapy is unknown. Parental HER2+ BC cells...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Mol Cancer Res
Main Authors: Sethunath, Vidyalakshmi, Hu, Huizhong, Angelis, Carmine De, Veeraraghavan, Jamunarani, Qin, Lanfang, Wang, Nicholas, Simon, Lukas M., Wang, Tao, Fu, Xiaoyong, Nardone, Agostina, Pereira, Resel, Nanda, Sarmistha, Griffith, Obi L., Tsimelzon, Anna, Shaw, Chad, Chamness, Gary C., Reis-Filho, Jorge S., Weigelt, Britta, Heiser, Laura M., Hilsenbeck, Susan G., Huang, Shixia, Rimawi, Mothaffar F., Gray, Joe W., Osborne, C. Kent, Schiff, Rachel
Formato: Artigo
Idioma:Inglês
Publicado: 2019
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6825570/
https://ncbi.nlm.nih.gov/pubmed/31420371
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1541-7786.MCR-19-0756
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares